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Abstract
Increased binge alcohol consumption has been reported among adolescents as compared to adults 
in both humans and rodent models, and has been associated with serious long-term health 
consequences. However, the neurochemical mechanism for age differences in binge drinking 
between adolescents and adults has not been established. The present study was designed to 
evaluate the mechanistic role of the cannabinoid CB1 receptor in adolescent and adult binge 
drinking. Binge consumption was established in adolescent and adult male C57BL/6J mice by 
providing access to 20% alcohol or 1% sucrose for 4 h every other day. Pretreatment with the CB1 
antagonist/inverse agonist AM-251 (0, 1, 3, and 10 mg/kg) in a Latin square design dose-
dependently reduced adolescent alcohol consumption to adult levels without altering adult intake. 
AM-251 (3 mg/kg) also reduced adolescent but not adult sucrose consumption. Adolescent 
reductions in alcohol and sucrose were not associated with alterations in open-field locomotor 
activity or thigmotaxis. These findings point to age differences in CB1 receptor activity as a 
functional mediator of adolescent-typical increased binge drinking as compared to adults. 
Developmental alterations in endocannabinoid signaling in the adolescent brain may therefore be 
responsible for the drinking phenotype seen in this age group.
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1. Introduction
Adolescence, or the period between childhood and adulthood, is an evolutionarily conserved 
developmental period characterized by physical and behavioral changes as organisms 
mature. Drug use is commonly initiated during adolescence, perhaps due to the increased 
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risk-taking, novelty-seeking and impulsive behaviors exhibited by this vulnerable age group 
(Crews et al., 2007; Spear, 2000). Like most drugs of abuse, alcohol use is usually initiated 
in adolescence (Johnston et al., 2012), and adolescent consumption of alcohol has been 
associated with greater risk of alcoholism over the lifespan (Dawson et al., 2008). In 
particular, binge drinking is more frequently reported in adolescent than adult populations 
(Nelson et al., 2009) and is associated with several long-term negative health consequences, 
including increased risk for the development of alcohol use disorders (Courtney and Polich, 
2009). However, the neurobiological differences between the adolescent and adult brain that 
may be responsible for behavioral differences and contribute to adolescent drug use and 
abuse have not yet been fully characterized.
During adolescence, significant changes in brain structure, receptor density and 
neurotransmitter levels occur as the brain matures. In particular, the endocannabinoid 
signaling systems undergoes significant structural and functional changes during 
adolescence in both humans and rodent models. In the human dorsal-lateral prefrontal 
cortex, CB1 mRNA peaks during childhood and remains high until adolescence, when it 
decreases to adult levels (Long et al., 2012). Similar patterns have been observed in the rat 
cortex with CB1 protein (Ellgren et al., 2008; Rodriguez de Fonseca et al., 1993) and mRNA 
(Heng et al., 2011; Van Waes et al., 2012). The endogenous ligands for the CB1 receptor, 
anandamide (AEA) and 2-arachidonoylglycerol (2-Ag), also experience significant flux 
during adolescent development, as do many of the enzymes responsible for their synthesis 
and degradation (Ellgren et al., 2008; Lee et al., 2013; Rubino et al., 2015; Wenger et al., 
2002). These alterations in the endocannabinoid systems of the adolescent brain have a net 
effect of increasing CB1 inhibition of synaptic activity in juveniles and disinhibiting cortical 
output as the brain matures into adulthood (Heng et al., 2011). Decreased cortical control of 
sensorimotor brain regions has been associated with lack of inhibitory control over behavior, 
a behavioral characteristic of adolescence. Indeed, the cannabinoid systems have been 
shown to play a role in adolescent-typical behaviors. Interaction with a non-familiar social 
partner increases AEA levels in the adolescent rat brain (Marco et al., 2011), and inhibiting 
the degradation of AEA in the adolescent brain enhances social play behavior (Trezza et al., 
2012). Inhibiting AEA degradation also reduces impulsive responding in an intolerance-to-
delay task among maternally deprived rats (Marco et al., 2007). Recently, Schneider et al. 
demonstrated that enhanced activity of the CB1 receptor in adult rats creates adolescent-
typical behavioral phenotypes, including increased novelty seeking, social interaction, 
impulsivity, and sensitivity to the rewarding effects of cocaine (Schneider et al., 2015). 
Additionally, in a human adolescent sample polymorphisms in the CNR1 gene, which 
encodes the CB1 receptor, were associated with self-reported impulsive behavior 
(Buchmann et al., 2015). Thus, the endocannabinoid systems undergo significant 
developmental regulation during adolescence, and may be involved in adolescent-typical 
behaviors that contribute to increased risk for drug use and abuse.
In studies with adult rodents and humans, a role for cannabinoid signaling in alcohol use and 
abuse has also been established. Acute alcohol exposure reduces CB1 receptor expression in 
the adult mouse brain (Basavarajappa et al., 1998) and increases AEA and 2-AG 
concentrations in vitro (Basavarajappa and Hungund, 1999; Basavarajappa et al., 2008). 
CB1 receptor availability has also been shown to decrease in the cortex of human alcoholics 
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(Ceccarini et al., 2014), and SNPs in the human CNR1 gene have been associated with 
alcoholism (Schmidt et al., 2002). Modulation of CB1 signaling has been shown to alter 
alcohol consumption in adult rodents. Pharmacological activation of CB1 has generally 
produced increases in alcohol self-administration (Alen et al., 2009; Linsenbardt and 
Boehm, 2009; Vinod et al., 2008) whereas pharmacological inactivation (Cippitelli et al., 
2005; Vinod et al., 2008) and genetic deletion (Lallemand and de Witte, 2005; Racz et al., 
2003) of the CB1 receptor has led to decreased alcohol intake and preference in adults (see 
Pava & Woodward, 2012 for review). These studies establish the CB1 receptor as both a 
target of alcohol’s activity in the adult brain as well as a functional modulator of alcohol 
consumption in rodents.
Developmental differences in the effects of cannabinoid signaling on alcohol intake have 
received limited investigation to date. Wang et al. (2003) compared young adult (post-natal 
day 42–70) and older adult (PND 182–336) CB1 knockout and wild type mice for alcohol 
intake and preference. Young adult CB1 knockout mice showed reduced alcohol preference 
and a trend for reduced intake (dose) as compared to wild type controls, whereas older adult 
CB1 knockout mice were not different than wild type. These results suggest that some of the 
regulation of alcohol consumption by CB1 activity may be age-dependent, although the 
study did not directly compare adolescent to adult mice. One additional study has also 
demonstrated that the CB1 agonist WIN 55,212-2 increased anxiety-related behaviors and 
increased 24-hour ethanol consumption in adolescent but not adult rats (Klugmann et al., 
2011). These studies provide preliminary evidence that developmental stage may be a factor 
in cannabinoid-mediated alcohol consumption, but more work is needed to establish a 
functional role for cannabinoid regulation of adolescent alcohol consumption.
The current studies were designed to examine the effects of CB1 receptor inhibition on 
alcohol consumption in adolescent and adult male C57BL/6J mice, an inbred mouse strain 
that has been shown to consume alcohol in a binge-like manner and achieve intoxicating 
doses in binge models (Agoglia et al., 2015; Holstein et al., 2011). We utilized a model of 
binge-like alcohol consumption in order to reflect the pattern of drinking behavior most 
commonly reported by adolescents in the clinical literature (Courtney and Polich, 2009; 
Miller et al., 2007). The CB1 antagonist/inverse agonist AM-251 was used to inhibit activity 
of the CB1 receptor. Additionally, we examined effects of this compound on locomotor 
activity, anxiety-like behavior, and consumption of the non-drug reinforcer sucrose. Our 
findings provide new evidence for developmental differences in sensitivity to 
pharmacological blockade of CB1 receptor activity, both in binge-like alcohol consumption 
and related behaviors.
2. Methods
2.1. Subjects
All animal procedures were carried out in accordance with the NIH Guide to Care and Use 
of Laboratory Animals (NRC, 2011) and approved by the Internal Review Board of the 
University of North Carolina, Chapel Hill. Male adolescent (postnatal day [PND] 21) and 
adult (PND 63 ± 2) C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME) were housed in 
standard cages with a small PVC pipe for environmental enrichment. Mice were singly 
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housed to measure individual alcohol intake, consistent with previous studies (Rhodes et al., 
2005; Thiele et al., 2014). Food and water were available ad libitum in home cages except 
where noted. The colony room was maintained on a 12-h light/dark cycle (lights on at 20:00) 
at 21 °C. All experimental manipulations and testing occurred during the dark cycle.
2.2. Drugs
Alcohol drinking solutions (v/v) were prepared by diluting 95% ethanol (Pharmco Products 
Inc., Brookfield, CT) with water. Sucrose drinking solutions (w/v) were prepared by 
dissolving sucrose in water. The CB1 antagonist/inverse agonist AM-251 (Tocris 
Bioscience; Ellisville, MO) was suspended in 25% β-cyclodextrin (Sigma-Aldrich, St. Louis, 
MO) and injected in doses of 0, 1.0, 3.0 and 10.0 mg/kg i.p. with a 30 min pretreatment 
time. All drug solutions were freshly prepared each day of testing.
2.3. Binge drinking procedure
Binge drinking was established in mice as previously described (Agoglia et al., 2015; 
Holstein et al., 2011). All subjects (N = 36) were given one week upon arrival (on 
experimental day 0, see Fig. 1) at our facility to acclimate to our colony environment. 
During acclimation, habituation injections were administered on experimental days 4 and 6. 
On experimental day 7, beginning 3 h into the dark cycle (10:00 AM) on PND 28 
(adolescent) and 72 (adult), home cage water bottles were removed and replaced with a 
double ball-bearing drinking tube containing 20% (v/v) ethanol (n = 12/age) or 1% (w/v) 
sucrose (n = 6/age) respectively in each experiment. Drinking tubes were removed after 2 h 
of access at 12:00 PM and fluid consumption was recorded. Alcohol access was restricted to 
2 h on the first day of drinking to avoid excessive intake that might lead to aversive effects 
which could limit subsequent alcohol drinking. The following day (experimental day 8), 
habituation injections were again administered. On experimental day 9, tubes were again 
placed on home cages at 10:00 AM and left in place for 4 h with removal at 2:00 PM. Mice 
had access to the tubes for 4 h a day, every other day, for the remainder of the experiments 
(Fig. 1.) Additional habituation injections were administered on an additional non-drinking 
day (experimental day 10) as well as 30 min before tube access on the two drinking days 
prior to drug testing (experimental days 11 and 13) for a total of six days of habituation 
injections in all, two on drinking days and four on non-drinking days.
Beginning on PND 36/80, each drinking session was preceded by an injection of AM-251 or 
vehicle. The alcohol drinking experiment utilized a Latin square design to test four doses of 
AM-251 (0, 1.0, 3.0 and 10.0 mg/kg) within subjects. The sucrose drinking experiments 
tested the lowest effective dose of AM-251 in the alcohol experiment (3.0 mg/kg) in a 
between-subjects design.
2.4. Locomotor testing
Following the completion of alcohol drinking, on PND 44 (adolescent) or PND 88 (adult) 
mice were injected with either vehicle or AM-251 (1 mg/kg, 30-min pretreatment) prior to a 
locomotor activity test (n = 6/treatment/age). Open field activity was measured in Plexiglas 
activity monitor chambers (27.9 cm2; ENV-510, Med Associates, Georgia, VT) connected to 
computers for data collection (Hodge et al., 1999; Stevenson et al., 2008). Two sets of 16 
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pulse-modulated infrared photobeams were located on opposite walls and recorded X–Y 
ambulatory movements. The mouse’s position in the open field was assessed every 100 ms 
to quantify distance traveled (in meters).
2.5. Data analysis
Alcohol intake data were reported as grams of alcohol per kilogram of body weight and 
sucrose intake data were reported as milliliters of fluid consumed per kilogram of body 
weight. One adolescent mouse in the alcohol drinking experiment was excluded from the 
analysis due to consistently low levels of alcohol intake (<1 g/kg in 4 h). Alcohol intake data 
were analyzed via two-way repeated measures ANOVA (Age × Dose) with one-way 
repeated measures ANOVA separately within age groups as planned comparisons. Holm–
Sidak’s multiple comparisons test was used for all post-hoc analyses. Sucrose intake was 
analyzed via Student’s t-test. Open field locomotor data were collapsed into 20 min time 
bins and activity was assessed via two-way repeated measures ANOVA (Dose × Time) 
separately within each age. Locomotor data were further analyzed for potential age or drug-
induced differences in anxiety-like behavior in an open-field test. Thigmotaxis was evaluated 
by comparing distance (cm) traveled in the center zone (inner 25% of the area) to distance 
traveled in the periphery (outer 75% of the area) as previously described (Agoglia et al., 
2015; Hodge et al., 2002). α was set at 0.05 for all comparisons. All analyses were 
performed using Prism v. 6.0 (GraphPad, La Jolla, CA).
3. Results
3.1. Baseline drinking and body weight
Adolescent alcohol consumption averaged 3.88 g/kg and adult intake averaged 3.99 g/kg 
over the four-hour drinking session prior to drug testing (Table 1). Sucrose consumption 
averaged 97.64 mL/kg in adolescents and 82.71 mL/kg in adults. No significant age 
differences in consumption prior to drug administration emerged (p > 0.05 for all 
comparisons). To test for potential age differences in injection stress, alcohol intake on 
experimental day 9 (no injection) was compared to alcohol intake on experimental day 11 
(vehicle habituation injection 30 min prior to drinking) separately within each age group. In 
both adolescents and adults, no differences in alcohol consumption were observed between 
days 9 and 11 (p > 0.05 for both comparisons, data not shown.) Additionally, body weight 
measurements taken before drug administration and after four days of repeated drug 
administration were compared for adolescents and adults. Adolescent body weight increased 
significantly over days and adult body weight did not change between measurements (Table 
2), with both ages showing body weights similar to those reported previously (Agoglia et al., 
2015) indicating no major adverse effects of drug treatment.
3.2. Effect of CB1 inhibition on binge-like alcohol drinking
Following a 30 minute pretreatment with the CB1 receptor antagonist/inverse agonist 
AM-251, a significant main effect of Age emerged, F (1, 21) = 5.52, p < 0.05. A main effect 
of Dose was also observed, F (3, 63) = 16.86, p < 0.0001. In adolescent mice, a planned one-
way ANOVA revealed a main effect of Dose, F (2.46) = 7.67, p < 0.01. Holm–Sidak’s 
multiple comparisons test revealed that the 1.0 mg/kg, 3.0 mg/kg and 10 mg/kg doses 
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significantly reduced alcohol consumption in adolescent mice (Fig. 2A). In adult mice, an 
effect of Dose was also significant [F (2.23) = 8.87, p < 0.0001]. However, Holm–Sidak’s 
multiple comparisons test indicated that only the 10.0 mg/kg dose of AM-251 significantly 
reduced alcohol consumption in adult mice (Fig. 2B) indicating age-dependent differences in 
dose sensitivity. Direct comparison of adolescent intake at the lowest effective dose (1.0 
mg/kg) and adult intake under vehicle conditions failed to find significant differences, 
indicating that adolescent alcohol intake had been reduced to adult levels at this dose [t(21) 
= 0.086, p > 0.05].
3.3. Effect of CB1 receptor inhibition on binge-like sucrose drinking
To determine if the effects of the CB1 antagonist/inverse agonist AM-251 were selective for 
alcohol consumption, or representative of effects on other reinforcing solutions, adolescent 
and adult mice were pretreated with the lowest effective dose of AM-251 (3.0 mg/kg) prior 
to a four-hour sucrose consumption test. AM-251 pretreatment significantly reduced sucrose 
consumption in adolescent mice [t (5) = 3.30, p < 0.05, Fig. 2C] but failed to significantly 
alter sucrose drinking in adult mice (p > 0.05, Fig. 2D). Direct comparison of adolescent 
sucrose intake with AM-251 pretreatment and adult intake under vehicle conditions failed to 
find significant differences, indicating that adolescent sucrose intake had been reduced to 
adult levels [t(10) = 0.34, p > 0.05].
3.4. Effect of CB1 receptor inhibition on open-field locomotor activity
To determine if the effects of CB1 inhibition with AM-251 were associated with alterations 
in general locomotor behavior, adolescent and adult mice were pretreated with the lowest 
effective dose of AM-251(1.0 mg/kg) 30 min prior to a two hour open-field locomotor 
behavior assay. In adolescent mice, AM-251 pretreatment failed to alter locomotor activity 
(p > 0.05, Fig. 3A). However, in adult mice AM-251 pretreatment resulted in a significant 
main effect of dose, F(1,10) = 5.16, p < 0.05 (Fig. 3B), suggesting that the 1.0 mg/kg dose of 
AM-251 reduced locomotor activity in adults but not adolescents.
To determine whether pretreatment with AM-251 was associated with alterations in anxiety-
like behaviors, adolescent and adult mice were evaluated for thigmotaxis during the open-
field locomotor testing. Both adolescents (Fig. 3C) and adults (Fig. 3D) spent approximately 
20% of the session in the center of the open field, and neither age displayed any alterations 
in time spent in the center following AM-251 pretreatment (p > 0.05). Additionally, a direct 
comparison of vehicle-treated adolescent and adult mice failed to show any age differences 
in thigmataxis [F (1,10) = 0.26, p > 0.05; data not shown.]
4. Discussion
The endocannabinoid CB1 receptor is the most abundant G protein-coupled receptor in the 
mammalian brain (Marsicano and Lutz, 1999), and has been shown to play a critical role in 
both neuronal development (Gaffuri et al., 2012) and reward-related behaviors (Panagis et 
al., 2014). However, the specific regulation of alcohol consumption by cannabinoid 
signaling during the adolescent developmental period has not yet been reported. Here, we 
show that the CB1 receptor antagonist/inverse agonist AM-251 reduces binge-like alcohol 
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and sucrose consumption in male C57BL/6J mice. However, adolescent mice were more 
sensitive than adults to this effect, displaying reductions in alcohol and sucrose drinking 
following AM-251 (1 or 3 mg/kg); doses that were ineffective at modulating intake in adults. 
We further report reduced sensitivity to the locomotor effects of AM-251 in adolescent mice, 
but no age or drug differences in thigmotaxis following AM-251 pretreatment. Together, 
these findings provide evidence of differential sensitivity to pharmacological manipulation 
of the CB1 receptor in adolescent and adult mice, and point to endocannabinoid signaling as 
a possible mechanism for age differences in alcohol consumption.
The drinking model employed in the present experiments resulted in significant age 
differences in alcohol and sucrose consumption such that adolescent mice consumed more 
alcohol g/kg and sucrose mL/kg than adult mice. This finding is in agreement with previous 
reports of greater alcohol and sucrose consumption among adolescent rodents (Agoglia et 
al., 2015; Brunell and Spear, 2005; Maldonado et al., 2008). Data from surveys of human 
alcohol users suggest that alcohol use is usually initiated during adolescence, and adolescent 
alcohol intake has also been reported to be higher than adult intake using human subjects 
(Courtney and Polich, 2009; Harford et al., 2005; Johnston et al., 2012). Thus, the drinking 
method employed in the present studies appears to be an appropriate model of adolescent-
typical binge drinking. Although we did not assess blood alcohol levels in the present 
experiments, previous reports from our lab have demonstrated that both adolescent and adult 
mice achieve binge levels of blood alcohol concentration (>80 mg/dL) in this limited access 
procedure (Agoglia et al., 2015; Holstein et al., 2011).
Pretreatment with the CB1 antagonist/inverse agonist AM-251 suggested increased 
sensitivity to cannabinoid modulation in adolescent as compared to adult mice, with all 
doses tested (1, 3 and 10 mg/kg) reducing alcohol consumption in adolescents, whereas only 
the high dose (10 mg/kg) reduced alcohol consumption in adults. Adolescent alcohol 
consumption was reduced by 28%, from 5.4 g/kg to 3.9 g/kg, at the 1 mg/kg dose. Notably, 
this reduction in alcohol consumption brought adolescent intake to the level of untreated 
adult mice, who averaged 4.1 g/kg under vehicle conditions. The effect at this dose appears 
to be selective for the excessive alcohol consumption exhibited by adolescents, as adult 
alcohol intake was not significantly reduced at this dose. Adolescent sucrose consumption 
was also reduced to adult levels after pretreatment with the 3 mg/kg dose of AM-251. 
Adolescent sucrose intake decreased from 131.1 mL/kg under vehicle conditions to 97.6 
mL/kg after 3 mg/kg of AM-251, putting adolescent intake in line with average adult sucrose 
intake (90.2 mL/kg). Consistent with the alcohol experiments, 3 mg/kg AM-251 did not 
significantly reduce adult sucrose consumption. Thus, inhibition of the CB1 receptor with 
AM-251 appears to blunt the adolescent-typical phenotype of increased binge alcohol and 
sucrose drinking and bring adolescent consumption to a more moderate adult-like level. This 
finding points to activity of the CB1 receptor as a mediator of the increased alcohol and 
sucrose consumption typically displayed by adolescents as compared to adults.
Decreases in alcohol consumption may also be due to alterations in alcohol metabolism as a 
result of AM-251 treatment. We did not assess blood alcohol concentration in the present 
experiments, nor have any previous studies determined the effects of AM-251 on alcohol 
metabolism. However, the CB1 receptor inverse agonist/antagonist SR141716A has a similar 
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mechanism of action as AM-251 and induces similar decreases in alcohol consumption. 
Previous studies have found that SR141716A pretreatment does not alter blood alcohol 
concentration in rats (Lallemand et al., 2001; Serra et al., 2001). These previous reports 
make actions of AM-251 on alcohol metabolism less likely. However, in future studies it will 
be important to assess blood alcohol levels with and without AM-251 pretreatment to 
definitively address this question.
Adult mice displayed a reduction in open-field locomotor activity following pretreatment 
with 1.0 mg/kg AM-251. Therefore, the reduction in adult alcohol consumption at the 10 
mg/kg dose should be considered in light of potential gross locomotor effects and not 
specific effects on alcohol drinking. In contrast, adolescent mice did not show any effect of 
AM-251 pretreatment on open-field locomotor activity. This finding indicates additional age 
differences in the behavioral effects of CB1 receptor inhibition, as adolescents appear to 
have reduced sensitivity to the locomotor effects of AM-251. Additionally, modulation of 
CB1 activity has been shown to alter anxiety-related behaviors, and age differences in 
sensitivity to the anxiogenic effects of CB1 activation in adolescents and adults have been 
reported (Klugmann et al., 2011). The current experiments failed to detect any effect of 
AM-251 on thigmotaxis in either adolescents or adults. This result suggests that the age 
differences in the effects of AM-251 on alcohol and sucrose consumption are likely 
independent of any anxiety-related effect of this drug as measured by the open-field 
thigmotaxy assay. Injection itself is a potential stressor, and adolescents have been shown to 
be more sensitive to some stressors than adults (Spear, 2000). We therefore compared 
adolescent and adult alcohol intake on a day without injections (experimental day 9) and a 
day with vehicle injection prior to drinking (experimental day 11). No differences in alcohol 
intake between days emerged in either age group, suggesting that injection stress was not 
significantly different between ages. Additionally, we compared adolescent and adult mice 
treated with vehicle injections directly in the open-field locomotor activity assay. No age 
differences in thigmataxis emerged, indicating that adolescents did not display greater 
anxiety-like behavior than adults after injection.
The effects of the CB1 antagonist/inverse agonist AM-251 on alcohol drinking reported here 
are reminiscent of those observed by Wang et al. (2003), who found that pretreatment with 
the CB1 antagonist/inverse agonist SR141716A reduced alcohol consumption in young 
adults but not older mice. Further, in the present study, adolescents were sensitive to an 
AM-251-induced decrease in sucrose consumption whereas adults showed no effect of 
AM-251 pretreatment, indicating that the effects of CB1 inhibition in adolescents reduced 
consumption of reinforcing solutions generally. The relationship between age differences in 
behavioral effects of CB1 inhibition and the altered expression of the CB1 receptor in the 
adolescent brain remains unclear. Adolescents display increased CB1 receptor expression, 
which may reduce sensitivity to CB1 modulation owing to the greater number of receptors 
needed to be occupied achieve a significant proportion of activation; i.e. a higher dose of 
AM-251 would be predicted to be necessary in adolescents to reach behavioral significance. 
In contrast, we observed increased behavioral sensitivity of adolescent mice to CB1 
inhibition, which may be explained by receptor “spareness”, or increased efficacy of the 
compound in adolescent mice, leading to behavioral effects despite a smaller proportion of 
occupied receptors (Rang, 2006). The underlying biology of the adolescent endocannabinoid 
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system contributing to this increased sensitivity to AM-251 is likewise unknown. However, 
adolescent mice have been shown to have altered functional coupling between the CB1 
receptor and G proteins as compared with adult mice (Moore et al., 2010; Wang et al., 
2003), which is a plausible explanation for age differences in sensitivity to CB1 inhibition. 
Although previous reports have shown that G protein expression reaches adult levels in the 
mouse cortex by PND 25 (Ihnatovych et al., 2002), age differences in CB1 receptor 
trafficking to the plasma membrane or the influence of CB1 accessory proteins could explain 
differences in functional coupling of CB1 in adolescents and adults. Direct manipulation of 
the CB1 receptor in the adolescent brain using genetic or pharmacological strategies would 
help to clarify the molecular mechanism driving the age differences in sensitivity to CB1 
antagonism/inverse agonism.
The CB1 receptor is involved in appetite and consummatory behaviors (Jager and Witkamp, 
2014), and previous studies have reported decreases in body weight following pretreatment 
with the cannabinoid antagonist/inverse agonist AM-251 (Merroun et al., 2013). The within-
subjects design of the present studies made drug effects on body weight more difficult to 
detect, owing to the lack of completely untreated mice for comparison. However, body 
weights of adolescent and adult mice were compared prior to drug treatment and after four 
days of repeated administration of AM-251. Adolescent body weight increased in a normal 
developmental trajectory (Agoglia et al., 2015), and adult body weight remained unchanged 
before and after treatment with either drug. The relatively short exposure period and lower 
doses used in the present experiments do not appear to alter body weight in adolescent or 
adult mice. We also did not observe gross developmental defects in adolescent mice treated 
with AM-251 as indexed by normal body weight and locomotor activity in an open field.
In summary, the current study provides evidence of altered behavioral sensitivity to 
pharmacological inhibition of the CB1 receptor in adolescent mice. Administration of the 
CB1 antagonist/inverse agonist AM-251 reduced binge alcohol and sucrose consumption in 
both adolescent and adult mice. However, adolescent alcohol and sucrose consumption were 
reduced at all doses tested, and intake of both solutions decreased to adult levels. Adult 
alcohol and sucrose intake were reduced only at the highest dose, and adults displayed 
reductions in locomotor activity absent in adolescent mice. These experiments provide new 
evidence for age differences in the behavioral pharmacology of the CB1 signaling systems, 
which may be due to well-characterized alterations in the CB1 systems during adolescent 
brain development. Further, these findings point to developmental differences in CB1 
signaling as a potential regulator of age differences in the consumption of reinforcing 
solutions. Mechanistic studies aimed at the brain regions responsible for these age 
differences and the long-term consequences of adolescent alcohol exposure would 
definitively establish a role for cannabinoid signaling in the adolescent brain on alcohol.
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Fig. 1. 
Timeline of adolescent and adult drinking. (A) Binge-like alcohol drinking. (B) Binge-like 
sucrose drinking. Each box represents one day. Top numbering describes the experimental 
day of each phase of the experiment, and bottom numbering describes the age of adolescent 
and adult mice in post-natal days (PND) at each time point during the experiment. Gray 
boxes marked “A” indicate alcohol drinking days and “S” indicate sucrose drinking days, 
respectively. Unfilled arrows indicate habituation vehicle injections, solid arrows indicate 
drinking sessions preceded by a drug injection.
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Fig. 2. 
Effects of CB1 inhibition on binge-like alcohol and sucrose consumption. Adolescent (A) 
and adult (B) alcohol intake was reduced by pretreatment with the CB1 antagonist/inverse 
agonist AM-251. Adolescent (C) but not adult (D) sucrose intake was reduced by 
pretreatment with AM-251. Asterisks indicate significant differences from vehicle with 
Holm–Sidak’s multiple comparisons test/Student’s t-test, * p < 0.05, *** p < 0.001.
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Fig. 3. 
Effects of CB1 inhibition on open-field locomotor activity. The CB1 antagonist/inverse 
agonist AM-251 did not alter adolescent locomotor activity (A), but reduced locomotor 
activity in adult mice in a time-dependent manner (B). Insets show total distance traveled 
over the two-hour test period; * = p < 0.05. AM-251 pretreatment did not alter time spent in 
the center of the open field in either adolescents or adults (C and D).
Agoglia et al. Page 15
Pharmacol Biochem Behav. Author manuscript; available in PMC 2016 June 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Agoglia et al. Page 16
Table 1
Baseline alcohol intake in adolescent and adult mice. Mean alcohol consumption in grams of alcohol per 
kilogram of bodyweight (±SEM) of adolescent and adult mice on the three drinking days prior to drug testing. 
No Inj. indicates drinking days without injections, and Hab. Inj. indicates drinking days preceded by 
habituation injections.
Age
Alcohol Intake (g/kg)
Day 9 (No Inj.) Day 11 (Hab. Inj.) Day 13 (Hab. Inj.)
Adolescent 3.60±0.46 3.80±0.51 4.11±0.35
Adult 4.27±0.38 4.36±0.31 4.67±0.28
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Table 2
Effect of CB1 inhibition on body weight. Mean body weight (±SEM) of adolescent (post-natal day [PND] 34) 
and adult mice (PND 78) before and after administration of the CB1 antagonist/inverse agonist AM-251 (PND 
42/86, respectively).
Before AM-251 After AM-251
Age (PND) Body-weight (g) Age (PND) Body-weight (g)
Adolescent 34 20.02 ± 0.28 42 22.91 ± 0.30
Adult 78 25.27 ± 0.36 86 26.72 ± 0.43
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